Forte Biosciences (FBRX) Net Cash Flow Growth (5y) (2021 - 2026)
Forte Biosciences (FBRX) Net Cash Flow Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Forte Biosciences | 1.36 Bn | 1.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.15% |
| Dec 31, 2025 | -19.40% |
| Sep 30, 2025 | -10.94% |
| Jun 30, 2025 | 40.77% |
| Mar 31, 2025 | 18.98% |
| Dec 31, 2024 | 58.25% |
| Sep 30, 2024 | -5.19% |
| Jun 30, 2024 | -18.29% |
| Mar 31, 2024 | 7.40% |
| Dec 31, 2023 | -20.33% |
| Sep 30, 2023 | 90.01% |
| Jun 30, 2023 | -22.92% |
| Mar 31, 2023 | 22.12% |
| Dec 31, 2022 | 40.31% |
| Sep 30, 2022 | 44.73% |
| Jun 30, 2022 | -15.12% |
| Mar 31, 2022 | -27.66% |
| Dec 31, 2021 | -31.81% |
| Sep 30, 2021 | -27.80% |
| Jun 30, 2021 | -59.64% |